blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3627152

EP3627152 - SCREENING METHOD [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  21.02.2020
Database last updated on 13.07.2024
FormerThe international publication has been made
Status updated on  23.11.2018
Most recent event   Tooltip21.05.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Takeda Pharmaceutical Company Limited
1-1 Doshomachi 4-chome Chuo-ku
Osaka-shi, Osaka 541-0045 / JP
[2020/13]
Inventor(s)01 / KIMURA, Haruhide
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1 Muraoka-Higashi 2-chome
Fujisawa-shi Kanagawa 251-0012 / JP
02 / SAKO, Yuu
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1 Muraoka-Higashi 2-chome
Fujisawa-shi Kanagawa 251-0012 / JP
03 / MATSUDA, Satoru
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1 Muraoka-Higashi 2-chome
Fujisawa-shi Kanagawa 251-0012 / JP
04 / SHIMIZU, Yuji
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1 Muraoka-Higashi 2-chome
Fujisawa-shi Kanagawa 251-0012 / JP
05 / KURIMOTO, Emi
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1 Muraoka-Higashi 2-chome
Fujisawa-shi Kanagawa 251-0012 / JP
06 / MANDAI, Takao
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1 Muraoka-Higashi 2-chome
Fujisawa-shi Kanagawa 251-0012 / JP
07 / TANAKA, Maiko
c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED
26-1 Muraoka-Higashi 2-chome
Fujisawa-shi Kanagawa 251-0012 / JP
 [2020/13]
Representative(s)Meissner Bolte Partnerschaft mbB
Patentanwälte Rechtsanwälte
Postfach 86 06 24
81633 München / DE
[N/P]
Former [2020/13]Held, Stephan
Meissner Bolte Patentanwälte
Rechtsanwälte Partnerschaft mbB
Widenmayerstraße 47
80538 München / DE
Application number, filing date18802166.117.05.2018
[2020/13]
WO2018JP19208
Priority number, dateUS201762508609P19.05.2017         Original published format: US 201762508609 P
[2020/13]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018212312
Date:22.11.2018
Language:JA
[2018/47]
Type: A1 Application with search report 
No.:EP3627152
Date:25.03.2020
Language:EN
[2020/13]
Search report(s)International search report - published on:JP22.11.2018
(Supplementary) European search report - dispatched on:EP25.01.2021
ClassificationIPC:G01N33/50, G01N33/15
[2021/08]
CPC:
A61P25/28 (EP); G01N33/944 (EP,US); G01N33/15 (US);
A61K45/06 (US); G01N2333/4703 (EP,US); G01N2500/04 (EP,US);
G01N2500/20 (EP,US) (-)
Former IPC [2020/13]G01N33/50, A61K45/00, A61P25/28, G01N33/15
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/13]
TitleGerman:SCREENING-VERFAHREN[2020/13]
English:SCREENING METHOD[2020/13]
French:PROCÉDÉ DE CRIBLAGE[2020/13]
Entry into regional phase19.11.2019Translation filed 
19.11.2019National basic fee paid 
19.11.2019Search fee paid 
19.11.2019Designation fee(s) paid 
19.11.2019Examination fee paid 
Examination procedure19.11.2019Examination requested  [2020/13]
20.08.2021Amendment by applicant (claims and/or description)
Fees paidRenewal fee
30.03.2020Renewal fee patent year 03
28.05.2021Renewal fee patent year 04
18.05.2022Renewal fee patent year 05
23.05.2023Renewal fee patent year 06
21.05.2024Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]  - MICHELLE F HOMSHER ET AL, "High-Throughput Agonist Shift Assay Development for the Analysis of M1-Positive Allosteric Modulators", SLAS DISCOVERY SOCIETY FOR LABORATORY AUTOMATION AND SCREENING, (20170101), vol. 22, no. 8, pages 1060 - 1066, XP055763523 [Y] 1-8 * page 1061, column r, paragraph 2 - page 1062, column r, paragraph 2; figures 1-4 *
 [Y]  - BRIANA J. DAVIE ET AL, "Synthesis and Pharmacological Evaluation of Analogues of Benzyl Quinolone Carboxylic Acid (BQCA) Designed to Bind Irreversibly to an Allosteric Site of the M 1 Muscarinic Acetylcholine Receptor", JOURNAL OF MEDICINAL CHEMISTRY, (20140605), vol. 57, no. 12, doi:10.1021/jm500556a, ISSN 0022-2623, pages 5405 - 5418, XP055612844 [Y] 1-8 * table 1 *

DOI:   http://dx.doi.org/10.1021/jm500556a
 [A]  - CONN P JEFFREY ET AL, "Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders", NATURE REVIEWS DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB, vol. 13, no. 9, doi:10.1038/NRD4308, ISSN 1474-1776, (20140901), pages 692 - 708, (20140901), XP037115031 [A] 1-8 * page 695, column l, paragraph 1 *

DOI:   http://dx.doi.org/10.1038/nrd4308
 [A]  - JENNIFER E. DAVOREN ET AL, "Discovery of the Potent and Selective M1 PAM-Agonist N -[(3 R ,4 S )-3-Hydroxytetrahydro-2 H -pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects", JOURNAL OF MEDICINAL CHEMISTRY, (20160714), vol. 59, no. 13, doi:10.1021/acs.jmedchem.6b00544, ISSN 0022-2623, pages 6313 - 6328, XP055422238 [A] 1-8 * the whole document *

DOI:   http://dx.doi.org/10.1021/acs.jmedchem.6b00544
 [A]  - JERRI M. ROOK ET AL, "Diverse Effects on M 1 Signaling and Adverse Effect Liability within a Series of M 1 Ago-PAMs", ACS CHEMICAL NEUROSCIENCE, US, (20161221), vol. 8, no. 4, doi:10.1021/acschemneuro.6b00429, ISSN 1948-7193, pages 866 - 883, XP055568055 [A] 1-8 * the whole document *

DOI:   http://dx.doi.org/10.1021/acschemneuro.6b00429
 [A]  - A. ABDUL-RIDHA ET AL, "Mechanistic Insights into Allosteric Structure-Function Relationships at the M1 Muscarinic Acetylcholine Receptor", JOURNAL OF BIOLOGICAL CHEMISTRY, (20141017), vol. 289, no. 48, doi:10.1074/jbc.M114.604967, ISSN 0021-9258, pages 33701 - 33711, XP055377423 [A] 1-8 * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.M114.604967
International search[A]JP2007509152  [A] 1-7* , & WO 2005/042475 A2 & US 2005/0096387 A1 & US 2007/0275959 A1 & US 2011/0144177 A1 & EP 1689704 A2 & EP 2314571 A2 & CN 1898201 A & KR 10-2007-0085033 A *;
 [A]WO2011049731  (MERCK SHARP & DOHME [US], et al) [A] 1-7 * , & US 2012/0196845 A1 & US 2014/0364395 A1 & EP 2490692 A1 *;
 [A]WO2014077401  (TAKEDA PHARMACEUTICAL [JP]) [A] 1-7 * , & JP 6211530 B2 & US 2015/0307497 A1 & EP 2921480 A1 *;
 [A]WO2015163485  (TAKEDA PHARMACEUTICAL [JP]) [A] 1-7 * , & JP 2017-513894 A & US 2015/0307451 A1 & EP 3134386 A1 & CN 106536508 A & KR 10-2016-0143852 A *;
 [A]JP2017501233  [A] 1-7 * , & WO 2015/110370 A1 & US 2016/0326144 A1 & EP 3097094 A1 & CN 105793259 A & KR 10-2016-0098500 A *;
 [A]  - DAVIE, B. J. et al., "Synthesis and Pharmacological Evaluation of Analogues of Benzyl Quinolone Carboxylic Acid (BQCA) Designed to Bind Irreversibly to an Allosteric Site of the M1 Muscarinic Acetylcholine Receptor", Journal of Medicinal Chemistry, (20140523), vol. 57, no. 12, pages 5405 - 5418, XP055612844 [A] 1-7

DOI:   http://dx.doi.org/10.1021/jm500556a
by applicantWO2010059773
 WO2011049731
 WO2013129622
 WO2014077401
 WO2015163485
 WO2015174534
 WO2015190564
 WO2016208775
 WO2017069173
    - Nature Reviews Drug Discovery, (20070000), vol. 6, pages 721 - 733
    - Eur. J. Biochem., (19840000), vol. 138, page 9
    - WOOTTEN, D., Nat Rev Drug Discov., (20130800), vol. 12, no. 8, pages 630 - 44
    - PRICE, M.R., Mol. Pharmacol., (20051100), vol. 68, no. 5, pages 1484 - 95
    - DAVIE, B.J., J. Med. Chem., (20140626), vol. 57, no. 12, pages 5405 - 18
    - "Shin Saibo Kogaku Jikken Protocol", Saibo Kogaku, Shujunsha, (19950000), pages 263 - 267
    - Virology, (19730000), vol. 52, page 456
    - Science, (19520000), vol. 122, page 501
    - Virology, (19590000), vol. 8, page 396
    - The Journal of the American Medical Association, (19670000), vol. 199, page 519
    - Proceeding of the Society for the Biological Medicine, (19500000), vol. 73, page 1
    - CHU, R., Sci. Rep., (20141208), vol. 4, page 7360
    - WHITEHURST, C.E. et al., J. Biomol. Screen., (20060300), vol. 11, no. 2, pages 194 - 207
    - BAKSH, M.M. et al., Nat Biotechnol., (20110400), vol. 29, no. 4, pages 357 - 60
    - Nat Rev Drug Discov., (20090000), vol. 8, no. 1, pages 41 - 54
    - Trends Pharmacol Sci., (20070000), vol. 28, no. 8, pages 382 - 9
    - Proceedings of the National Academy of Science of the United States of America, (20090000), vol. 106, no. 37, pages 15950 - 5
    - BYMASTER et al., Brain. Res., (19980608), vol. 795, no. 1-2, pages 179 - 90
    - PATELFREEDMAN, Eur. J. Pharmacol., (19940517), vol. 267, no. 3, pages 329 - 34
    - TRINQUET et al., Anal Biochem., (20061101), vol. 358, no. 1, pages 126 - 35
    - TING J.T. et al., Methods Mol Biol., (20140000), vol. 1183, pages 221 - 42
    - GULLEDGE et al., J. Neurosci., (20090805), vol. 29, no. 31, pages 9888 - 9902
 WO2017JP09529
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.